Drug-induced hyperuricaemia and gout.
Ben Salem C, Slim R, Fathallah N, Hmouda H.
Rheumatology (Oxford). 2017 May 1;56(5):679-688. doi: 10.1093/rheumatology/kew293.
Secondary gout.
GARDNER FH, NATHAN DG.
Med Clin North Am. 1961 Sep;45:1273-82. doi: 10.1016/s0025-7125(16)33834-2.
Diagnosis, treatment, and prevention of gout.
Hainer BL, Matheson E, Wilkes RT.
Am Fam Physician. 2014 Dec 15;90(12):831-6.
Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N.
N Engl J Med. 2005 Dec 8;353(23):2450-61. doi: 10.1056/NEJMoa050373.
Gout Keratitis: A Case of Peripheral Ulcerative Keratitis Secondary to Gout With a Review of the Literature.
Yazdanyar A, Rizzuti AE, Mechel E, Denisova K, Lazzaro DR.
Cornea. 2018 Mar;37(3):379-381. doi: 10.1097/ICO.0000000000001415.
Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for recurrent nephrolithiasis among patients with pre-existing nephrolithiasis or gout: target trial emulation studies.
McCormick N, Yokose C, Lu N, Wexler DJ, Aviña-Zubieta JA, De Vera MA, Chigurupati S, Tan K, Chen C, McCoy R, Curhan GC, Choi HK.
BMJ. 2024 Oct 30;387:e080035. doi: 10.1136/bmj-2024-080035.
Hyperuricemia and gout.
Lioté F.
Curr Rheumatol Rep. 2003 Jun;5(3):227-34. doi: 10.1007/s11926-003-0072-y.
Efficacy and Safety of Dotinurad Versus Febuxostat for the Treatment of Gout: A Randomized, Multicenter, Double-Blind, Phase 3 Trial in China.
Sun J, Wang Y, Cheng Y, Guo D, Hu J, Liu D, Gao Z, Li C, Lu Y, Kong X, Liu Y, Jiang Z, Yi B, Zhang H, Xu B, Yu S, Kokan R, Ishikawa K, Kawakatsu M, Zhang Z.
Arthritis Rheumatol. 2025 Dec;77(12):1757-1766. doi: 10.1002/art.43261. Epub 2025 Sep 8.
Gout and incidence of 12 cardiovascular diseases: a case-control study including 152 663 individuals with gout and 709 981 matched controls.
Ferguson LD, Molenberghs G, Verbeke G, Rahimi K, Rao S, McInnes IB, McMurray JJV, Sattar N, Conrad N.
Lancet Rheumatol. 2024 Mar;6(3):e156-e167. doi: 10.1016/S2665-9913(23)00338-7.
Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial.
Helget LN, Davis-Karim A, O'Dell JR, Mikuls TR, Newcomb JA, Androsenko M, Brophy MT, England BR, Ferguson R, Pillinger MH, Neogi T, Wu H, Palevsky PM.
Am J Kidney Dis. 2024 Nov;84(5):538-545. doi: 10.1053/j.ajkd.2024.04.017. Epub 2024 Jun 19.
